Published in J Clin Endocrinol Metab on July 14, 2010
The amazing osteocyte. J Bone Miner Res (2011) 5.32
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One (2011) 2.10
Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int (2014) 2.03
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int (2011) 1.61
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int (2011) 1.23
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2012) 1.13
Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci (2012) 1.12
Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest (2011) 1.12
Osteocyte-driven bone remodeling. Calcif Tissue Int (2013) 1.08
Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res (2012) 1.08
Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab (2012) 1.08
Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood (2012) 1.05
The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol (2013) 1.03
Effects of PTH on osteocyte function. Bone (2012) 1.03
Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology (2011) 1.02
Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int (2011) 1.00
Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab (2011) 0.99
Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies. Curr Osteoporos Rep (2012) 0.99
Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone (2011) 0.98
Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab (2011) 0.96
Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab (2011) 0.96
Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) (2014) 0.94
Sclerostin levels during growth in children. Osteoporos Int (2011) 0.93
Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab (2012) 0.93
Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int (2011) 0.91
Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int (2012) 0.90
A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am (2014) 0.89
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89
Vascular calcification and renal bone disorders. ScientificWorldJournal (2014) 0.88
The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res (2014) 0.88
Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab (2014) 0.86
Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J Cell Physiol (2012) 0.86
Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone (2012) 0.85
Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol (2014) 0.84
Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int (2014) 0.83
Serum sclerostin levels vary with season. J Clin Endocrinol Metab (2013) 0.83
Serum sclerostin levels in healthy men over 50 years of age. J Bone Miner Metab (2013) 0.81
Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats. Osteoporos Int (2014) 0.81
Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations. J Clin Endocrinol Metab (2014) 0.80
Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine. J Bone Miner Metab (2015) 0.80
T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone. Ann N Y Acad Sci (2015) 0.79
Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome. Osteoporos Int (2013) 0.79
Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int J Endocrinol (2014) 0.79
Spinal Cord Injury and Osteoporosis: Causes, Mechanisms, and Rehabilitation Strategies. Int J Phys Med Rehabil (2013) 0.78
Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab (2014) 0.78
Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression. Ann N Y Acad Sci (2015) 0.77
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul) (2014) 0.77
Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients. Osteoporos Int (2015) 0.77
Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. PLoS One (2015) 0.76
Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.75
Serum sclerostin decreases following 12months of resistance- or jump-training in men with low bone mass. Bone (2016) 0.75
DMP-1-mediated Ghr gene recombination compromises skeletal development and impairs skeletal response to intermittent PTH. FASEB J (2015) 0.75
Hormonal and systemic regulation of sclerostin. Bone (2016) 0.75
Simulated Interventions to Ameliorate Age-Related Bone Loss Indicate the Importance of Timing. Front Endocrinol (Lausanne) (2016) 0.75
Short-term intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone. Bone Rep (2016) 0.75
Osteocytes and Skeletal Pathophysiology. Curr Mol Biol Rep (2015) 0.75
[Biochemical markers of bone metabolism and their importance]. Z Rheumatol (2016) 0.75
Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. Int Urol Nephrol (2017) 0.75
New anabolic therapies for osteoporosis. Intern Emerg Med (2017) 0.75
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Regulation of bone mass by Wnt signaling. J Clin Invest (2006) 5.59
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet (2002) 4.00
Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology (2007) 3.46
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA (2004) 3.35
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet (2002) 2.21
Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 2.19
Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab (2010) 2.05
Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem (2007) 1.79
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem (2002) 1.76
Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res (2007) 1.74
Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab (2010) 1.62
PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res (2003) 1.61
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone (2009) 1.26
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol (2007) 1.19
One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res (2009) 0.99
In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res (2000) 0.97
Regulation of bone turnover by sex steroids in men. J Bone Miner Res (2008) 0.95
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA (2003) 2.81
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Rapid skeletal turnover in a radiographic mimic of osteopetrosis. J Bone Miner Res (2014) 2.00
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood (2002) 1.84
Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res (2002) 1.81
Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am (2005) 1.80
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70
Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res (2010) 1.65
Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab (2002) 1.61
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol (2005) 1.48
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res (2002) 1.46
Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res (2004) 1.43
Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood (2013) 1.42
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res (2012) 1.37
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res (2003) 1.33